Identification

Name
Metolazone
Accession Number
DB00524  (APRD01109)
Type
Small Molecule
Groups
Approved
Description

A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. [PubChem]

Structure
Thumb
Synonyms
  • 2-Methyl-3-O-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone
  • 7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide
  • 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-O-tolyl-6-quinazolinesulfonamide
  • Metolazon
  • Metolazona
  • Métolazone
  • Metolazonum
External IDs
SR 720-22
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetolazoneTablet10 mg/1OralUpstate Pharma, LLC1973-11-27Not applicableUs
MetolazoneTablet2.5 mg/1OralUpstate Pharma, LLC1973-11-27Not applicableUs
MetolazoneTablet2.5 mg/1OralAphena Pharma Solutions Tennessee, Inc.1973-11-27Not applicableUs65580 0643 71 nlmimage10 394b1cb8
MetolazoneTablet2.5 mg/1OralAvera Mc Kennan Hospital2015-04-16Not applicableUs
MetolazoneTablet5 mg/1OralUpstate Pharma, LLC1973-11-27Not applicableUs65580 0644 71 nlmimage10 08450428
ZaroxolynTablet5 mg/1OralUnither Pharmaceuticals1973-11-272016-01-13Us
ZaroxolynTablet2.5 mg/1OralCarilion Materials Management1973-11-27Not applicableUs
ZaroxolynTablet2.5 mgOralSanofi Aventis1974-12-31Not applicableCanada
ZaroxolynTablet5 mgOralAventis Pharma Ltd.1974-12-312003-07-22Canada
Zaroxolyn Tab 10mgTablet10 mgOralRhone Poulenc Rorer1974-12-311998-08-12Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetolazoneTablet5 mg/1OralEon Labs, Inc.2003-12-19Not applicableUs
MetolazoneTablet5 mg/1OralPhysicians Total Care, Inc.2004-04-27Not applicableUs
MetolazoneTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-01-18Not applicableUs
MetolazoneTablet2.5 mg/1OralCardinal Health2011-01-14Not applicableUs
MetolazoneTablet5 mg/1OralMylan Institutional2005-02-01Not applicableUs
MetolazoneTablet2.5 mg/1OralMylan Pharmaceuticals2004-01-06Not applicableUs
MetolazoneTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-12-19Not applicableUs
MetolazoneTablet10 mg/1OralCarilion Materials Management2004-10-19Not applicableUs
MetolazoneTablet2.5 mg/1OralEon Labs, Inc.2003-12-19Not applicableUs
MetolazoneTablet2.5 mg/1OralPhysicians Total Care, Inc.2004-07-06Not applicableUs
International/Other Brands
Diulo / Diurem (Cipla) / Metadure (Micro Labs) / Metenix (IFET) / Metolaz (Navana) / Metoral (Dr. Reddy's) / Metoz (Centaur) / Metozone (Ying Yuan) / Mykrox (Celltech) / Pavedal (Pharma Investi) / Zaroxolyn / Zytanix (Zydus)
Categories
UNII
TZ7V40X7VX
CAS number
17560-51-9
Weight
Average: 365.835
Monoisotopic: 365.06008979
Chemical Formula
C16H16ClN3O3S
InChI Key
AQCHWTWZEMGIFD-UHFFFAOYSA-N
InChI
InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23)
IUPAC Name
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide
SMILES
CC1NC2=CC(Cl)=C(C=C2C(=O)N1C1=CC=CC=C1C)S(N)(=O)=O

Pharmacology

Indication

For the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.

Structured Indications
Pharmacodynamics

Metolazone is a quinazoline diuretic, with properties generally similar to the thiazide diuretics. A proximal action of metolazone has been shown in humans by increased excretion of phosphate and magnesium ions and by a markedly increased fractional excretion of sodium in patients with severely compromised glomerular filtration. This action has been demonstrated in animals by micropuncture studies.

Mechanism of action

The actions of metolazone result from interference with the renal tubular mechanism of electrolyte reabsorption. Metolazone acts primarily to inhibit sodium reabsorption at the cortical diluting site and to a lesser extent in the proximal convoluted tubule. Sodium and chloride ions are excreted in approximately equivalent amounts. The increased delivery of sodium to the distal tubular exchange site results in increased potassium excretion. Metolazone does not inhibit carbonic anhydrase. The antihypertensive mechanism of action of metolazone is not fully understood but is presumed to be related to its saluretic and diuretic properties.

TargetActionsOrganism
ASolute carrier family 12 member 3
inhibitor
Human
Absorption

Peak blood levels are obtained within 2 to 4 hours of oral administration. The rate and extent of absorption are formulation dependent.

Volume of distribution
Not Available
Protein binding

50-70% bound to erythrocytes, up to 33% bound to plasma proteins, 2-5% of the drug in circulation is unbound

Metabolism

Not substantially metabolized. 70-95% is excreted unchanged in urine via glomerular filtration and active tubular secretion. Undergoes enterohepatic recycling.

Route of elimination

Most of the drug is excreted in the unconverted form in the urine.

Half life

Approximately 14 hours.

Clearance
Not Available
Toxicity

Symptoms of overdose include difficulty breathing, dizziness, dizziness on standing up, drowsiness, fainting, irritation of the stomach and intestines, and lethargy leading to coma.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Metolazone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Metolazone.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Metolazone.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Metolazone.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Metolazone.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metolazone.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Metolazone.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Metolazone is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Aceclofenac.Approved
AcemetacinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Acemetacin.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Metolazone.Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Metolazone can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Metolazone.Experimental
AlaproclateAlaproclate may increase the hyponatremic activities of Metolazone.Experimental
AlclofenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Metolazone.Approved
AlcuroniumThe serum concentration of Metolazone can be increased when it is combined with Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Metolazone.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Metolazone.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metolazone.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Metolazone is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Metolazone.Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Metolazone.Approved
AlminoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metolazone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Metolazone.Illicit
AlprenololMetolazone may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanMetolazone may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Metolazone.Approved
AmifostineMetolazone may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Metolazone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Metolazone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Metolazone.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Metolazone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Metolazone is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Metolazone.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Metolazone.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Metolazone.Investigational
AnisodamineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Metolazone can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine.Approved
ApocyninThe therapeutic efficacy of Metolazone can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Metolazone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Metolazone.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Metolazone.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Metolazone.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metolazone.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Metolazone.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Metolazone.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Metolazone.Approved
AtracuriumThe serum concentration of Metolazone can be increased when it is combined with Atracurium.Experimental
Atracurium besylateThe serum concentration of Metolazone can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Metolazone can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Metolazone.Investigational
BalsalazideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Metolazone.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Metolazone.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Metolazone.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Metolazone.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Metolazone.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Metolazone.Investigational
BenactyzineThe serum concentration of Metolazone can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Metolazone.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metolazone.Withdrawn
BenorilateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Metolazone can be increased when it is combined with Benzatropine.Approved
BepridilMetolazone may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Metolazone.Approved
BethanidineBethanidine may increase the hypotensive activities of Metolazone.Approved
BevoniumThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Metolazone.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Metolazone.Experimental
BimatoprostMetolazone may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Metolazone can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Metolazone is combined with Bisoprolol.Approved
BornaprineThe serum concentration of Metolazone can be increased when it is combined with Bornaprine.Experimental
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Metolazone.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Metolazone.Approved, Investigational
BQ-123Metolazone may increase the hypotensive activities of BQ-123.Investigational
BretyliumThe risk or severity of adverse effects can be increased when Metolazone is combined with Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Metolazone.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Metolazone.Experimental
BromfenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Metolazone.Approved, Investigational
BucillamineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Metolazone.Approved
BufexamacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bufexamac.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Metolazone.Withdrawn
BumadizoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Metolazone.Approved, Investigational
BupranololMetolazone may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Metolazone.Experimental
CafedrineMetolazone may increase the hypotensive activities of Cafedrine.Investigational
CalcidiolMetolazone may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolMetolazone may increase the hypercalcemic activities of Calcipotriol.Approved
CalciumMetolazone may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateMetolazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium CarbonateMetolazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Calcium CitrateMetolazone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.Approved
Calcium glubionateMetolazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateMetolazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateMetolazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
Calcium lactateMetolazone may decrease the excretion rate of Calcium lactate which could result in a higher serum level.Approved, Experimental, Vet Approved
Calcium lactate gluconateMetolazone may decrease the excretion rate of Calcium lactate gluconate which could result in a higher serum level.Experimental
Calcium laevulateMetolazone may decrease the excretion rate of Calcium laevulate which could result in a higher serum level.Experimental
Calcium pangamateMetolazone may decrease the excretion rate of Calcium pangamate which could result in a higher serum level.Experimental
Calcium PhosphateMetolazone may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Metolazone is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Metolazone is combined with Candesartan.Approved
CandoxatrilMetolazone may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Metolazone can be decreased when used in combination with Carbaspirin calcium.Experimental
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Metolazone.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Metolazone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Metolazone.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Metolazone.Withdrawn
CarprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Metolazone.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Metolazone is combined with Carvedilol.Approved, Investigational
CaseinMetolazone may decrease the excretion rate of Casein which could result in a higher serum level.Approved
CastanospermineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Metolazone.Approved, Investigational
ChloroquineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Metolazone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Metolazone can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metolazone.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Metolazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Metolazone.Approved, Investigational
CicletanineMetolazone may increase the hypotensive activities of Cicletanine.Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Metolazone.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Metolazone.Approved
CitalopramCitalopram may increase the hyponatremic activities of Metolazone.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Metolazone.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Metolazone.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Metolazone.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Metolazone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Metolazone.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Metolazone.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Clonidine.Approved
ClonixinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Clonixin.Approved
CloranololMetolazone may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Metolazone.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metolazone.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Metolazone.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Metolazone.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Metolazone.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Metolazone.Approved
CryptenamineMetolazone may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Metolazone can be decreased when used in combination with Curcumin.Investigational
CyclopenthiazideMetolazone may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclopentolateThe serum concentration of Metolazone can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideMetolazone may increase the hypotensive activities of Cyclothiazide.Approved
CymarinThe risk or severity of adverse effects can be increased when Metolazone is combined with Cymarin.Experimental
D-LimoneneThe therapeutic efficacy of Metolazone can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Metolazone.Investigational
DarifenacinThe serum concentration of Metolazone can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Metolazone.Approved
DelaprilMetolazone may increase the hypotensive activities of Delapril.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Metolazone.Investigational
DeserpidineMetolazone may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metolazone.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Metolazone can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Metolazone.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Metolazone.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Metolazone.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Metolazone.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Metolazone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Metolazone.Vet Approved
DexetimideThe serum concentration of Metolazone can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metolazone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metolazone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Metolazone.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Metolazone is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Metolazone can be increased when it is combined with Dicyclomine.Approved
diethylnorspermineMetolazone may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Metolazone.Approved
DiflunisalThe therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Metolazone.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Metolazone.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Metolazone.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metolazone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metolazone.Experimental, Illicit
DihydrotachysterolMetolazone may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Metolazone.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Metolazone.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Metolazone.Approved
DofetilideMetolazone may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideMetolazone may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Metolazone is combined with Doxazosin.Approved
DoxercalciferolMetolazone may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Metolazone.Investigational
DroxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Metolazone.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone.Approved
DuloxetineMetolazone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Metolazone can be decreased when used in combination with E-6201.Investigational
EfonidipineMetolazone may increase the hypotensive activities of Efonidipine.Approved
EmeproniumThe serum concentration of Metolazone can be increased when it is combined with Emepronium.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Metolazone is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Enalapril.Approved, Vet Approved
EnalaprilatMetolazone may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Metolazone.Experimental
EpanololMetolazone may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the hypokalemic activities of Metolazone.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Metolazone can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Eplerenone.Approved
EpoprostenolMetolazone may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Eprosartan.Approved
EquileninEquilenin may increase the hypokalemic activities of Metolazone.Experimental
EquilinEquilin may increase the hypokalemic activities of Metolazone.Approved
ErgocalciferolMetolazone may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Metolazone.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone.Approved
EstroneEstrone may increase the hypokalemic activities of Metolazone.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Metolazone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.Approved
EtanautineThe serum concentration of Metolazone can be increased when it is combined with Etanautine.Experimental
EtanerceptThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Metolazone.Approved
EthenzamideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ethenzamide.Experimental
EthopropazineThe serum concentration of Metolazone can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone.Approved, Illicit
EtodolacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Metolazone.Approved
EtoricoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Metolazone.Illicit, Vet Approved
EtybenzatropineThe serum concentration of Metolazone can be increased when it is combined with Etybenzatropine.Experimental
Evening primrose oilThe therapeutic efficacy of Metolazone can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Metolazone.Approved, Investigational
exisulindThe therapeutic efficacy of Metolazone can be decreased when used in combination with exisulind.Investigational
FelbinacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen.Approved
FenoldopamMetolazone may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Metolazone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ferulic acid.Experimental
FesoterodineThe serum concentration of Metolazone can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metolazone.Approved
FloctafenineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Metolazone.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Metolazone.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
FlunixinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Metolazone.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Metolazone.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Metolazone.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Metolazone.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Metolazone.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Metolazone.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Metolazone.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Metolazone.Approved
FlurbiprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluvoxamineFluvoxamine may increase the hyponatremic activities of Metolazone.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Metolazone.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Metolazone.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metolazone.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Metolazone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide.Approved, Vet Approved
GallamineThe serum concentration of Metolazone can be increased when it is combined with Gallamine.Experimental
Gallamine TriethiodideThe serum concentration of Metolazone can be increased when it is combined with Gallamine Triethiodide.Approved
GitoformateThe risk or severity of adverse effects can be increased when Metolazone is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Metolazone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Metolazone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Metolazone.Approved
GlycopyrroniumThe serum concentration of Metolazone can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuacetisalThe therapeutic efficacy of Metolazone can be decreased when used in combination with Guacetisal.Experimental
GuanabenzMetolazone may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Metolazone.Approved
GuanazodineMetolazone may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Metolazone.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Metolazone is combined with Guanfacine.Approved, Investigational
GuanoclorMetolazone may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMetolazone may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMetolazone may increase the hypotensive activities of Guanoxan.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Metolazone.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Metolazone.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Metolazone.Experimental
HE3286HE3286 may increase the hypokalemic activities of Metolazone.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Metolazone.Approved, Illicit
HexamethoniumThe serum concentration of Metolazone can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
HigenamineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Higenamine.Investigational
HomatropineThe serum concentration of Metolazone can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Metolazone.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Metolazone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
HydroflumethiazideMetolazone may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone.Approved, Illicit
HyoscyamineThe serum concentration of Metolazone can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Metolazone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Metolazone.Investigational
Imidazole salicylateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Metolazone.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Metolazone.Approved
IndalpineIndalpine may increase the hyponatremic activities of Metolazone.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Indapamide.Approved
IndenololMetolazone may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Metolazone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Metolazone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Metolazone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Metolazone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone.Approved
Ipratropium bromideThe serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Metolazone.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metolazone.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metolazone.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Metolazone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Metolazone.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Metolazone.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Metolazone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Metolazone.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Metolazone.Investigational
IvabradineMetolazone may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Metolazone.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metolazone.Approved
KetoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Metolazone is combined with Labetalol.Approved
LacidipineMetolazone may increase the hypotensive activities of Lacidipine.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Metolazone is combined with Lanatoside C.Experimental
LatanoprostMetolazone may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineMetolazone may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Metolazone is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metolazone.Approved
LevodopaMetolazone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Metolazone.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Metolazone.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Metolazone.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Metolazone.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.Approved
LinsidomineMetolazone may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Metolazone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lisofylline.Investigational
LithiumMetolazone may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Metolazone.Illicit
LofexidineMetolazone may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Losartan.Approved
LoxoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanMetolazone may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineMetolazone may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.Approved, Investigational
MasoprocolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol.Approved
MazaticolThe serum concentration of Metolazone can be increased when it is combined with Mazaticol.Experimental
ME-609ME-609 may increase the hypokalemic activities of Metolazone.Investigational
MebanazineMebanazine may increase the hypotensive activities of Metolazone.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Metolazone.Approved
Mefenamic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Metolazone.Vet Approved
MeloxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Metolazone.Experimental
MesalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metolazone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metolazone.Approved, Illicit
MethanthelineThe serum concentration of Metolazone can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Metolazone is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Metolazone.Approved
MethoserpidineMetolazone may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Metolazone is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Metolazone.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metolazone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Metolazone is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Metolazone is combined with Metipranolol.Approved
MetixeneThe serum concentration of Metolazone can be increased when it is combined with Metixene.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Metolazone.Approved, Investigational
MetyrosineMetolazone may increase the hypotensive activities of Metyrosine.Approved
MibefradilMetolazone may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Metolazone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Metolazone.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Metolazone.Approved
MinaprineMinaprine may increase the hypotensive activities of Metolazone.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Metolazone.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Metolazone.Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Metolazone.Approved, Investigational
MizoribineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Metolazone.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Metolazone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Metolazone.Approved
MuzolimineMetolazone may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Metolazone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Metolazone is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naftifine.Approved
NaftopidilMetolazone may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone.Approved
NaproxenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Metolazone.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Metolazone.Investigational
NebivololThe risk or severity of adverse effects can be increased when Metolazone is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Metolazone.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Metolazone is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Metolazone.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Nicardipine.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Metolazone.Experimental
NicorandilNicorandil may increase the hypotensive activities of Metolazone.Approved
NifedipineThe risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineMetolazone may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineMetolazone may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Metolazone.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Metolazone.Approved
NitrendipineMetolazone may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metolazone.Approved
NitroaspirinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Metolazone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Metolazone.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Metolazone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Metolazone.Approved, Illicit
ObinutuzumabMetolazone may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Metolazone.Withdrawn
OleandrinThe risk or severity of adverse effects can be increased when Metolazone is combined with Oleandrin.Experimental
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Metolazone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metolazone.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Metolazone.Approved
OlopatadineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.Approved
OmapatrilatMetolazone may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Metolazone.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Metolazone.Approved
OrgoteinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Metolazone can be increased when it is combined with Orphenadrine.Approved
OtiloniumThe serum concentration of Metolazone can be increased when it is combined with Otilonium.Experimental
OuabainThe risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Metolazone is combined with Oxcarbazepine.Approved
OxitropiumThe serum concentration of Metolazone can be increased when it is combined with Oxitropium.Investigational
OxprenololMetolazone may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Metolazone can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Metolazone can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metolazone.Approved, Vet Approved
PancuroniumThe serum concentration of Metolazone can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Metolazone.Approved
ParecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Metolazone.Approved
ParicalcitolMetolazone may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Metolazone.Approved, Investigational
ParthenolideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Parthenolide.Investigational
PenbutololThe risk or severity of adverse effects can be increased when Metolazone is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
PentoliniumThe serum concentration of Metolazone can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metolazone.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Metolazone is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Metolazone.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Metolazone.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Metolazone.Approved, Withdrawn
PhenglutarimideThe serum concentration of Metolazone can be increased when it is combined with Phenglutarimide.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Metolazone.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Metolazone.Experimental
PhenoxybenzamineMetolazone may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metolazone.Withdrawn
PhentolamineMetolazone may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Metolazone.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Metolazone.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Metolazone is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metolazone.Approved
PipecuroniumThe serum concentration of Metolazone can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Metolazone.Approved
PirenzepineThe serum concentration of Metolazone can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Metolazone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Metolazone.Approved
PiroxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Metolazone.Withdrawn
PolythiazideMetolazone may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Metolazone.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Metolazone.Approved, Investigational
PranoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Pranoprofen.Experimental
PrasteronePrasterone may increase the hypokalemic activities of Metolazone.Approved, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Metolazone.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Metolazone.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Metolazone.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Metolazone.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Metolazone.Approved
ProcyclidineThe serum concentration of Metolazone can be increased when it is combined with Procyclidine.Approved
ProglumetacinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Metolazone can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Metolazone can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Metolazone.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Metolazone is combined with Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Metolazone is combined with Proscillaridin.Experimental
PTC299The therapeutic efficacy of Metolazone can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Metolazone is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Metolazone can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Metolazone.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Metolazone.Approved
RasagilineRasagiline may increase the hypotensive activities of Metolazone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone.Approved
RemikirenRemikiren may increase the hypotensive activities of Metolazone.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Metolazone.Approved, Investigational
RescinnamineMetolazone may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Metolazone.Approved
ResveratrolThe therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Metolazone.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Metolazone.Approved
RiociguatThe risk or severity of adverse effects can be increased when Metolazone is combined with Riociguat.Approved
RisperidoneMetolazone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Metolazone.Approved
RituximabMetolazone may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Metolazone.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Metolazone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Metolazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Metolazone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Metolazone.Approved
SafrazineSafrazine may increase the hypotensive activities of Metolazone.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Metolazone.Approved
SalsalateThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate.Approved
SaprisartanMetolazone may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Metolazone.Approved
ScopolamineThe serum concentration of Metolazone can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Metolazone can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Metolazone.Approved, Investigational, Vet Approved
SelexipagMetolazone may increase the hypotensive activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Metolazone can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Metolazone can be decreased when used in combination with Serrapeptase.Investigational
SertralineSertraline may increase the hyponatremic activities of Metolazone.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metolazone.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Metolazone.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone.Approved, Investigational
SitaxentanMetolazone may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Metolazone.Approved
Sodium phosphateMetolazone may increase the nephrotoxic activities of Sodium phosphate.Approved
SolifenacinThe serum concentration of Metolazone can be increased when it is combined with Solifenacin.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Metolazone.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.Approved
SpiraprilMetolazone may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone.Approved
SRT501The therapeutic efficacy of Metolazone can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Metolazone.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Metolazone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Metolazone.Approved, Investigational
TalinololMetolazone may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Metolazone.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metolazone.Approved
TarenflurbilThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Metolazone is combined with Telmisartan.Approved, Investigational
TemocaprilMetolazone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Metolazone.Approved
TeriflunomideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide.Approved
TerlipressinMetolazone may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineMetolazone may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Metolazone.Approved, Investigational, Withdrawn
TheodrenalineMetolazone may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
ThiopentalThiopental may increase the orthostatic hypotensive activities of Metolazone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metolazone.Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneMetolazone may increase the hypotensive activities of Tibolone.Approved
TicrynafenMetolazone may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Metolazone.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Metolazone.Approved
TinoridineThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Metolazone can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Metolazone.Approved
TizanidineThe risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone.Approved
TolazolineMetolazone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metolazone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin.Approved
TolonidineMetolazone may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Metolazone.Approved
TolterodineThe serum concentration of Metolazone can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateMetolazone may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metolazone.Approved
ToremifeneMetolazone may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Metolazone.Approved
TranilastThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metolazone.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Metolazone.Approved
TravoprostTravoprost may increase the hypotensive activities of Metolazone.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Metolazone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Metolazone.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Metolazone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone.Approved
TribenosideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tribenoside.Experimental
TrichlormethiazideMetolazone may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Metolazone.Experimental
TrimethaphanThe serum concentration of Metolazone can be increased when it is combined with Trimethaphan.Approved
TriptolideThe therapeutic efficacy of Metolazone can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Metolazone.Withdrawn
TropatepineThe serum concentration of Metolazone can be increased when it is combined with Tropatepine.Experimental
TropicamideThe serum concentration of Metolazone can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Metolazone can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Metolazone can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Metolazone.Approved, Investigational
UnoprostoneMetolazone may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Metolazone.Investigational
ValdecoxibThe therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Metolazone.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metolazone.Approved
VecuroniumThe serum concentration of Metolazone can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Metolazone.Approved
VerapamilThe risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.Approved
VilanterolVilanterol may increase the hypokalemic activities of Metolazone.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone.Approved, Investigational
VincamineMetolazone may increase the hypotensive activities of Vincamine.Experimental
VinpocetineMetolazone may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Metolazone.Approved, Investigational
XipamideMetolazone may increase the hypotensive activities of Xipamide.Experimental
XylometazolineMetolazone may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Metolazone.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Metolazone.Withdrawn
ZofenoprilMetolazone may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Take with food to reduce gastric irritation.

References

General References
  1. Rosenberg J, Gustafsson F, Galatius S, Hildebrandt PR: Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005 Aug;19(4):301-6. [PubMed:16189620]
External Links
Human Metabolome Database
HMDB14665
KEGG Drug
D00431
PubChem Compound
4170
PubChem Substance
46509058
ChemSpider
4026
BindingDB
25899
ChEBI
64354
ChEMBL
CHEMBL878
Therapeutic Targets Database
DAP000749
PharmGKB
PA164781022
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Metolazone
ATC Codes
C03BA08 — MetolazoneC03EA12 — Metolazone and potassium-sparing agentsG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 40:28.24 — Thiazide-like Diuretics
FDA label
Download (834 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers3
1RecruitingTreatmentCongestive Heart Failure (CHF) / Prophylaxis of cardiomyopathy1
2RecruitingTreatmentAcute Decompensated Heart Failure (ADHF)1
4CompletedTreatmentRapid Ventricular Response Atrial Fibrillation1
4Enrolling by InvitationTreatmentHeart Failure, Unspecified1
4TerminatedTreatmentAcute Decompensated Heart Failure (ADHF)1
Not AvailableUnknown StatusTreatmentHypernatremia / Respiratory Failure / Volume Overload1
Not AvailableWithdrawnTreatmentCongestive Heart Failure (CHF)2

Pharmacoeconomics

Manufacturers
  • Gd searle llc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Ucb inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral5 mg/1
TabletOral2.5 mg
TabletOral5 mg
TabletOral10 mg
Prices
Unit descriptionCostUnit
Zaroxolyn 10 mg tablet2.89USD tablet
Zaroxolyn 5 mg tablet2.75USD tablet
Metolazone 10 mg tablet1.8USD tablet
Zaroxolyn 2.5 mg tablet1.74USD tablet
Metolazone 5 mg tablet1.51USD tablet
Metolazone 2.5 mg tablet1.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)256 °CPhysProp
water solubility60.3 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.5Not Available
logS-3.78ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0407 mg/mLALOGPS
logP3.21ALOGPS
logP2.94ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)9.54ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.59 m3·mol-1ChemAxon
Polarizability36.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9972
Blood Brain Barrier+0.5944
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.7578
P-glycoprotein inhibitor INon-inhibitor0.8113
P-glycoprotein inhibitor IINon-inhibitor0.5921
Renal organic cation transporterNon-inhibitor0.9223
CYP450 2C9 substrateNon-substrate0.6466
CYP450 2D6 substrateNon-substrate0.8279
CYP450 3A4 substrateNon-substrate0.579
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5788
Ames testNon AMES toxic0.8234
CarcinogenicityNon-carcinogens0.7193
BiodegradationNot ready biodegradable0.9961
Rat acute toxicity1.8955 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9922
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0aor-1494000000-aae5f0a5c86e9d0828e2
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0bvi-2960000000-1eed022b28a6bb140f60

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinazolines. These are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolines
Alternative Parents
Toluenes / Secondary alkylarylamines / Organosulfonamides / Aryl chlorides / Vinylogous amides / Tertiary carboxylic acid amides / Aminosulfonyl compounds / Lactams / Amino acids and derivatives / Azacyclic compounds
show 5 more
Substituents
Quinazoline / Secondary aliphatic/aromatic amine / Toluene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Organosulfonic acid amide / Organic sulfonic acid or derivatives / Vinylogous amide
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
sulfonamide, organochlorine compound, quinazolines (CHEBI:64354)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name
SLC12A3
Uniprot ID
P55017
Uniprot Name
Solute carrier family 12 member 3
Molecular Weight
113138.04 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:23